Patient Preference and Adherence (Feb 2023)
Towards a Therapy for Geographic Atrophy: A Patient’s Experience
Abstract
Jamie Enoch,1 Arevik Ghulakhszian,2 Mandeep Sekhon,3 David P Crabb,1 Deanna J Taylor,1 Christiana Dinah2,4 1Department of Optometry and Visual Sciences, City, University of London, London, UK; 2Ophthalmology Department, London North West University Healthcare NHS Trust, Central Middlesex Hospital, London, UK; 3Centre for Applied Health and Social Care Research, Kingston and St George’s, University of London, London, UK; 4Department of Brain Sciences, Imperial College, London, UKCorrespondence: Christiana Dinah, Ophthalmology Department, London North West University Healthcare NHS Trust, Central Middlesex Hospital, Acton Lane, London, NW10 7NS, UK, Tel +44 208 453 2253, Email [email protected]: Geographic atrophy (GA) is the advanced form of the non-neovascular (dry) type of age-related macular degeneration. Presently, GA cannot be treated. However, new therapies administered by intravitreal injection are in late-stage development. These can slow down, but do not stop or reverse, GA progression. The acceptability of these emerging therapies to people with GA is currently unknown. The present case study explores the perspectives of a person living with GA who took part in the terminated Phase 3 clinical trial of Lampalizumab, a candidate intravitreal treatment for GA. We explored this patient’s perspective on the retrospective acceptability of regular Lampalizumab injections, and the prospective acceptability of future intravitreal therapies for GA.Patients and Methods: A 78-year-old woman living in the UK was recruited as part of a mixed-methods pilot study and interviewed by telephone, regarding: her experience of the Lampalizumab trial injections; and her thoughts regarding emerging intravitreal therapies for GA. The Framework Method was used for initial inductive analysis of the interview transcript. Subsequently, deductive analysis was undertaken, informed by the Theoretical Framework of Acceptability (TFA).Results: For this participant, intravitreal injections in the Lampalizumab trial were acceptable, although streamlining processes within the clinic would have improved the patient experience. Regarding prospective acceptability of new intravitreal therapies, the participant considered a delay in progression of GA a valuable goal. Potential discomfort, anxiety and inconvenience associated with regular intravitreal injections would be acceptable in the context of preserving her vision for as long as possible.Conclusion: Analysis of one participant’s experience demonstrates the value of exploring GA patients’ unique views on the acceptability of new intravitreal treatments. Larger prospective studies will provide more insight that help to optimise treatment design and delivery, thereby maximising likelihood of adherence and persistence when these therapies eventually arrive in clinic.Keywords: geographic atrophy, qualitative, case study, acceptability
